Zolbetuximab — now with the brand name Vyloy — is a monoclonal antibody to treat patients with advanced gastric and ...

Astellas Pharma Inc. (ALPMY, ALPMY) said that the U.S. Food and Drug Administration has approved VYLOY (zolbetuximab-clzb) in ...

FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to ...

Vyloy is the first CLDN 18.2-targeted treatment to reach the US market alongside Roche's Ventana CLDN18 RxDx Assay for identifying eligible patients.

Rechallenging patients with ICIs may not be beneficial in advanced RCC, but Tivozanib monotherapy shows promise as an ...

The FDA approved zolbetuximab (Vyloy), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, in combination with ...

Combined company will operate as TuHURA Biosciences, Inc. and advance pipeline of novel technologies to overcome resistance to cancer immunotherapy ...

It may soon be possible to determine which patients with a type of liver cancer called hepatocellular carcinoma would benefit from immunotherapy, according to a preclinical study by Weill Cornell ...

It may soon be possible to determine which patients with a type of liver cancer called hepatocellular carcinoma would benefit ...

Renal cell carcinoma (RCC) is the third most common cancer of the urinary system. There is a pressing need for specific biomarkers for advanced/metastatic RCC to enhance diagnostic accuracy and ...

Panelists discuss how the introduction of adjuvant immunotherapy has influenced their first-line treatment decisions for ...

Robot-assisted partial nephrectomy and image-guided percutaneous cryoablation for renal cell carcinoma (cT1) offer similar outcomes.